1. Regulatory Framework Governing Healthcare Transactions
Healthcare transactions operate within a complex web of federal and state regulations designed to protect patients, prevent fraud, and ensure the financial integrity of the healthcare system. The primary federal constraints stem from the Anti-Kickback Statute (AKS), which prohibits the knowing and willful offer, payment, solicitation, or receipt of remuneration in exchange for referrals of patients or services paid by federal healthcare programs. The Stark Law (Physician Self-Referral Law) imposes a strict liability standard, meaning intent is irrelevant; if a referral relationship and financial interest exist, the arrangement must fit within a statutory exception or face penalties regardless of the parties' subjective intent.
How Do Federal Anti-Kickback and Stark Law Restrictions Apply to Healthcare Transactions?
Federal anti-kickback and Stark law restrictions apply to healthcare transactions by requiring that any exchange of value between healthcare entities be structured in a way that does not incentivize referrals or violate self-referral prohibitions. Under the Anti-Kickback Statute, a healthcare provider cannot receive payment or other remuneration that is conditioned on, or substantially related to, the referral of patients or the ordering of services covered by Medicare, Medicaid, or other federal programs. The Stark Law goes further by creating an absolute prohibition on physician self-referral arrangements unless they fit within narrow statutory exceptions such as personal service contracts, equipment rental, or space rental, each with specific compliance requirements regarding fair market value, written agreements, and term limitations.
Violations of these statutes expose healthcare providers to civil penalties, exclusion from federal healthcare programs, and criminal prosecution. A transaction that fails to comply with these frameworks may be deemed void, forcing the parties to unwind the arrangement and potentially triggering audit and recovery actions by the Department of Health and Human Services Office of Inspector General.
What Role Do State Licensing and Corporate Practice of Medicine Laws Play?
State licensing and corporate practice of medicine laws play a critical role in restricting which entities can own, control, or operate healthcare practices and facilities. Many states, including New York, impose limitations on the ownership and governance of medical practices, requiring that physicians maintain professional and financial control over clinical decision-making. These laws often prohibit lay ownership or control of medical practices and restrict the ability of non-physician entities to employ physicians or direct their clinical judgment. When a healthcare transaction involves the transfer of a medical practice, merger of healthcare entities, or investment by a lay-owned company, the transaction structure must comply with state-specific corporate practice of medicine rules or risk contract unenforceability and regulatory sanctions.
Additionally, state licensing boards may require prior approval or notification of material changes in practice ownership or governance. Failure to obtain required state approvals before consummating a healthcare transaction can result in loss of medical licenses, operational injunctions, and civil penalties.
2. Common Structural Issues in Healthcare Transactions
Healthcare transactions frequently encounter structural problems that arise from the tension between commercial deal objectives and regulatory compliance requirements. Many parties attempt to structure transactions in ways that maximize financial benefit without fully accounting for the strict liability nature of Stark law or the breadth of anti-kickback statute prohibitions. Common pitfalls include mischaracterization of compensation, failure to document fair market value determinations, inadequate written agreements, and insufficient separation between clinical and administrative functions.
What Happens When Fair Market Value Is Not Properly Documented in a Healthcare Transaction?
When fair market value is not properly documented in a healthcare transaction, the arrangement becomes vulnerable to regulatory challenge and may be treated as a disguised kickback or prohibited self-referral. Fair market value is the price at which an asset or service would exchange between a willing buyer and a willing seller, neither being under pressure to buy or sell and both having reasonable knowledge of relevant facts. In the healthcare context, regulators and courts scrutinize valuations closely because inflated payments for assets, services, or practice acquisitions can mask improper incentives to refer patients or order services. The absence of a contemporaneous, written fair market value opinion from an independent valuation expert creates a significant compliance gap and shifts the burden to the healthcare provider to defend the reasonableness of the compensation arrangement.
Regulatory agencies view inadequate fair market value documentation as a red flag for potential fraud, and courts may void portions of the transaction or impose penalties. As a practical matter, healthcare providers should engage qualified valuation specialists early in the transaction process and ensure that all fair market value determinations are memorialized in writing with detailed methodologies and supporting analysis.
How Can Written Agreements Protect Healthcare Providers in Transactions?
Written agreements protect healthcare providers in transactions by creating a clear, contemporaneous record of the parties' intent, the economic terms, and the specific performance obligations of each party. A well-drafted written agreement should specify the scope of services, the compensation structure, the term of the arrangement, renewal or termination provisions, and representations regarding compliance with applicable law. The agreement should also include representations and warranties from each party that the transaction complies with anti-kickback and Stark law restrictions and that all required regulatory approvals have been obtained or are pending.
From a New York practice standpoint, healthcare transaction agreements should be reviewed by counsel experienced in both healthcare law and the specific regulatory regime applicable to the parties. Courts in New York may examine whether the written agreement demonstrates that the parties contemplated regulatory compliance and documented their good-faith efforts to structure the transaction lawfully. The absence of a written agreement or the presence of vague, informal understandings creates a significant evidentiary gap if a regulatory inquiry or dispute arises later.
3. Regulatory Approval Pathways and Compliance Considerations
Many healthcare transactions require regulatory approval or notification before they can be consummated. The specific approval pathway depends on the nature of the transaction, the entities involved, and the regulatory agencies with jurisdiction. Federal agencies with authority over healthcare transactions include the Centers for Medicare and Medicaid Services (CMS), the Department of Health and Human Services Office of Inspector General (OIG), and the Federal Trade Commission (FTC). State agencies typically include the state department of health, state medical board, and state attorney general's office.
What Regulatory Approvals Are Necessary before Closing a Healthcare Transaction?
Regulatory approvals necessary before closing a healthcare transaction vary depending on the transaction type and the entities involved. If the transaction involves the acquisition of a Medicare-enrolled provider, CMS may require notification and approval of the change in ownership or control. If the transaction involves a physician practice acquisition or merger, the state medical board may require notice of the change in practice structure and confirmation that the new arrangement complies with state corporate practice of medicine rules. If the transaction involves a health plan, hospital, or other regulated entity, the state insurance commissioner or department of health may require formal approval.
Additionally, if the transaction raises antitrust concerns (for example, a merger of competing healthcare providers in a concentrated market), the FTC or the Department of Justice Antitrust Division may challenge the transaction or condition approval on certain divestitures or behavioral remedies. Parties should identify all applicable regulatory requirements early in the transaction process and build approval timelines and contingencies into the deal structure. Closing a healthcare transaction without obtaining all required regulatory approvals can result in contract rescission, penalties, and loss of provider status.
How Should Healthcare Providers Document Compliance with Regulatory Requirements?
Healthcare providers should document compliance with regulatory requirements by creating a comprehensive compliance file that includes all regulatory approvals, fair market value opinions, written agreements, board resolutions, and legal opinions regarding compliance with anti-kickback and Stark law restrictions. This file should be maintained in a secure location and made available to internal compliance personnel and external auditors upon request. The compliance file demonstrates that the provider conducted due diligence and acted in good faith to structure the transaction lawfully.
Documentation should also include evidence of compliance review by qualified legal counsel, internal compliance assessments, and contemporaneous board minutes reflecting the board's consideration of regulatory compliance issues. Maintaining thorough documentation creates a strong defense in the event of a regulatory inquiry and demonstrates the provider's commitment to lawful structuring and operation of the transaction.
4. What Should Parties Review before Healthcare Transactions?
Before healthcare transactions are finalized, parties should confirm that ownership structures, compensation arrangements, licensing requirements, and referral relationships comply with applicable federal and state regulations. In my experience reviewing regulated transactions, issues identified during due diligence are often easier to address before closing than after a regulatory inquiry begins. A comprehensive review of fair market value documentation, written agreements, and regulatory approvals can help reduce compliance risks and support a legally sustainable transaction structure.
15 May, 2026
